BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Stock Price & Overview

NASDAQ:BGMSP • US23254L2079

3.15 USD
+0.13 (+4.3%)
Last: Mar 6, 2026, 08:02 PM

The current stock price of BGMSP is 3.15 USD. Today BGMSP is up by 4.3%. In the past month the price decreased by -4.55%.

BGMSP Key Statistics

1-Month Range2.97 - 4.15
Current BGMSP stock price positioned within its 1-month range.
Market Cap
15.435M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-80.13
Dividend Yield
19.05%

BGMSP Stock Performance

Today
+4.3%
1 Week
-4.55%
1 Month
-4.55%
3 Months
-24.46%
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

BGMSP Stock Chart

BIO GREEN MED SOLUTION - BGMS 6 PERP / BGMSP Daily stock chart

BGMSP Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to BGMSP.


Chartmill TA Rating
Chartmill Setup Rating
BGMSP Full Technical Analysis Report

BGMSP Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BGMSP. BGMSP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BGMSP Full Fundamental Analysis Report

BGMSP Earnings

Next Earnings DateMar 31, 2026
Last Earnings DateNov 10, 2025
PeriodQ3 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise 217.65%
BGMSP Earnings History

BGMSP Forecast & Estimates

For the next year, analysts expect an EPS growth of 39.49% and a revenue growth 88.68% for BGMSP


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y39.49%
Revenue Next Year88.68%
BGMSP Forecast & Estimates

BGMSP Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

BGMSP Financial Highlights

Over the last trailing twelve months BGMSP reported a non-GAAP Earnings per Share(EPS) of -80.13. The EPS increased by 96.34% compared to the year before.


Income Statements
Revenue(TTM)81.00K
Net Income(TTM)-6.97M
Industry RankSector Rank
PM (TTM) N/A
ROA -85.49%
ROE -98.28%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%96.97%
Sales Q2Q%710%
EPS 1Y (TTM)96.34%
Revenue 1Y (TTM)9.46%
BGMSP financials

BGMSP Ownership

Ownership
Inst Owners1.65%
Shares4.90M
Float1.57M
Ins Owners62.28%
Short Float %N/A
Short RatioN/A
BGMSP Ownership

BGMSP Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.21406.874B
AMGN AMGEN INC16.37199.203B
GILD GILEAD SCIENCES INC16.42178.678B
VRTX VERTEX PHARMACEUTICALS INC23.43116.013B
REGN REGENERON PHARMACEUTICALS16.5580.332B
ALNY ALNYLAM PHARMACEUTICALS INC42.6342.526B
INSM INSMED INC N/A30.205B
NTRA NATERA INC N/A28.081B
BIIB BIOGEN INC11.4427.132B
UTHR UNITED THERAPEUTICS CORP17.2720.958B
MRNA MODERNA INC N/A20.742B
EXAS EXACT SCIENCES CORP340.5719.757B
RVMD REVOLUTION MEDICINES INC N/A19.5B

About BGMSP

Company Profile

BGMSP logo image Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. The company provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.

Company Info

BIO GREEN MED SOLUTION - BGMS 6 PERP

Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi

KUALA LUMPUR NEW JERSEY MY

Employees: 0

BGMSP Company Website

BGMSP Investor Relations

Phone: 609085177330

BIO GREEN MED SOLUTION - BGMS 6 PERP / BGMSP FAQ

What does BGMSP do?

Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. The company provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.


Can you provide the latest stock price for BIO GREEN MED SOLUTION - BGMS 6 PERP?

The current stock price of BGMSP is 3.15 USD. The price increased by 4.3% in the last trading session.


Does BGMSP stock pay dividends?

BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) has a dividend yield of 19.05%. The yearly dividend amount is currently 0.


What is the ChartMill rating of BIO GREEN MED SOLUTION - BGMS 6 PERP stock?

BGMSP has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the upcoming dividend date for BIO GREEN MED SOLUTION - BGMS 6 PERP?

The next ex-dividend date for BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) is January 22, 2026.